HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

2019 ◽  
Author(s):  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Acute Myeloid

A Real Life Turkish Experience Of Venetoclax Treatment In High Risk Myelodysplastic Syndrome And Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Aliihsan Gemici ◽  
Fahir Ozkalemkas ◽  
Mehmet Hilmi Dogu ◽  
Atakan Tekinalp ◽  
Inci Alacacioglu ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Real Life ◽  
Acute Myeloid

Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status

2014 ◽  
Vol 14 (6) ◽  
pp. 509-513 ◽  
Author(s):  
Ali Al-Ameri ◽  
Ankit Anand ◽  
Mohamed Abdelfatah ◽  
Zeyad Kanaan ◽  
Tracy Hammonds ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Health Insurance ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Insurance Status ◽  
Health Insurance Status ◽  
Acute Myeloid

scholarly journals Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia ◽  
2018 ◽  
Vol 33 (2) ◽  
pp. 379-389 ◽  
Author(s):  
Jorge E. Cortes ◽  
Florian H. Heidel ◽  
Andrzej Hellmann ◽  
Walter Fiedler ◽  
B. Douglas Smith ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Newly Diagnosed ◽  
Low Dose Cytarabine ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document